|
|
10421 Pacific Center Court, Suite 150
San Diego, CA 92121 USA
phone:858-526-8000
fax:858-597-7040
|
|
| Symbol |
FVRL |
| Exchange |
NASDAQ |
| Founded |
2000 |
| Employees |
|
|
|
| www.favrille.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Immunotherapies for the treatment of cancer and immune system diseases. |
|
| Management |
| John P. Longenecker, Ph.D., President and CEO; Daniel P. Gold, Ph.D.,
Founder & Chief Scientific Officer; Tamara A. Seymour, Chief Financial Officer and Vice President of Finance and Administration; David Guy,
Chief Commercial Officer; Richard Murawski, Senior Vice-President of Operations; John F. Bender, Pharm.D., Vice-President of Clinical Research; Alice Wei, Vice-President, Regulatory Affairs and Quality |
| |
|
|
|
|
|
|
|
| Keywords |
| immunotherapy, cancer, immune system, lymphoma |
|
|
|
| Description |
|
Favrille, Inc. is a clinical development-stage company developing patient-specific active immunotherapies for lymphoma and disease of the immune system. |
|
|
| Funding |
| The Company has been funded through sales of preferred stock totaling $77 million. |
|
| Status |
| Favrille has completed enrollment in two Phase II clinical trials and entered a pivotal Phase III clinical trial for patients with follicular B-cell non-Hodgkin's lymphoma in July of 2004. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
